Zitian Chen
陈子天
Zitian Chen is the CEO of Sainuo Bio (赛纳生物), a domestic NGS gene sequencing instrument company founded in 2015 that uses proprietary technology to push sequencing accuracy to Q40 while driving down costs . The company has raised multiple funding rounds, including a Series C+ of hundreds of millions of RMB led by Source Code Capital in early 2023 and a subsequent round exceeding 100 million yuan by late 2025 . Chen holds a PhD and has represented Sainuo in public statements thanking investors and acknowledging government policy support . elsewhere's corpus does not cover his background prior to Sainuo or details beyond his role at the company.
AI-generated — may contain errors, please verify.
Coverage
MaHui | MaHui Member Sainuo Biotech Closes New Funding Round Exceeding 100 Million Yuan, Continues Focus on Core Gene Sequencing Technology
Source Code Capital | "Sainuo Biology" Completes Hundreds of Millions of RMB in Series C+ Funding, Led by Source Code Capital
With this round of capital, Sainuo Bio will stay true to its founding mission, leverage its team's proprietary R&D strengths, actively refine its product portfolio, and vigorously advance its commercialization efforts.
